Utilizing Pharmacogenomic Data in Perioperative Medicine: Feasibility, Value, and Inevitability

From the *Department of Anesthesia Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts

†Department of Anesthesiology, University of Utah, Salt Lake City, Utah.

Accepted for publication March 23, 2022.

a(i)The Clinical Pharmacogenetics Implementation Consortium (CPIC), an international group of volunteers that facilitate use of pharmacogenetic tests for patient care. See https://cpicpgx.org/, last accessed December 2021.

(ii)The Pharmacogene Variation (PharmVar) Consortium, a repository of pharmacogene variations and resource for clinical research and medical decision making. See https://www.pharmvar.org/, last accessed December 2021.

(iii)Table of Pharmacogenomic Biomarkers in Drug Labeling maintained by the United States Food and Drug Administration. See https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling, last accessed December 2021.

Funding: None.

The authors declare no conflict of interest.

Reprints will not be available from the authors.

Address correspondence to Ken B. Johnson, MD, Department of Anesthesiology, University of Utah, 30 N 1900 E, RM 3C444, Salt Lake City, UT 84132. Address e-mail to [email protected].

留言 (0)

沒有登入
gif